scispace - formally typeset
Journal ArticleDOI

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial

Reads0
Chats0
TLDR
In patients with STEMI undergoing primary PCI, anticoagulation with bivalirudin reduced the rates of net adverse clinical events and major bleeding at 1 year compared with treatment with heparin plus a GPI.
About
This article is published in The Lancet.The article was published on 2009-10-03. It has received 398 citations till now. The article focuses on the topics: Bivalirudin & Randomized controlled trial.

read more

Citations
More filters
Journal ArticleDOI

ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation

TL;DR: The once-in-a-lifetime treatment with Abciximab Intracoronary for acute coronary syndrome and a second dose intravenously for atrial fibrillation is recommended for adults with high blood pressure.
Journal ArticleDOI

Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium

TL;DR: Bleeding complications have been associated with an increased risk of subsequent adverse outcomes, including MI, stroke, stent thrombosis, and death, in patients with ACS and in those undergoing percutaneous coronary intervention (PCI) as well as in the long-term antithrombotic setting.
References
More filters
Journal ArticleDOI

Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions

TL;DR: Criteria for assessment of death, myocardial infarction, repeat revascularization, and stent thrombosis were developed and provide consistency across studies that can facilitate the evaluation of safety and effectiveness of these devices.
Journal ArticleDOI

Bivalirudin during Primary PCI in Acute Myocardial Infarction

TL;DR: In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events.
Journal ArticleDOI

Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes

TL;DR: In ACS patients without persistent ST-segment elevation, there is a strong, consistent, temporal, and dose-related association between bleeding and death, and a similar association was evident between major bleeding and ischemic events, including myocardial infarction and stroke.
Journal ArticleDOI

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.

TL;DR: Stent implantation (with or without abciximab therapy) should be considered the routine reperfusion strategy in experienced centers and when used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further improve outcomes.
Related Papers (5)